Clinical Trials Using Multitargeted Tyrosine Kinase Inhibitor PLX3397

Clinical trials are research studies that involve people. The clinical trials on this list are studying Multitargeted Tyrosine Kinase Inhibitor PLX3397. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-4 of 4
  • I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.
    Location: 20 locations

  • Pexidartinib and Sirolimus in Treating Patients with Sarcoma or Malignant Peripheral Nerve Sheath Tumors That Cannot Be Removed by Surgery

    This phase 1 / 2 trial studies the side effects and best dose of pexidartinib and sirolimus when given together and to see how well they work in treating patients with sarcoma or malignant peripheral nerve sheath tumors (MPNSTs) that has spread from the primary site (place where it started) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Pexidartinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sirolimus is used to decrease the body's immune response and may increase blood cell counts.Giving pexidartinib and sirolimus together may work better in treating patients with sarcoma or malignant peripheral nerve sheath tumors.
    Location: 5 locations

  • Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

    This study is designed to evaluate the discontinuation / re-treatment of pexidartinib therapy in previously treated participants with tenosynovial giant cell tumor (TGCT).
    Location: 4 locations

  • PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)

    Background: - Some people with cancer have solid tumors. Others have refractory leukemia. This doesn t go away after treatment. Researchers want to see if a drug called PLX3397 can shrink tumors or stop them from growing. Objectives: - To find the highest safe dose and side effects of PLX3397. To see if it helps treat certain types of cancer. Eligibility: - People ages 3 22 with a solid tumor or leukemia that has returned or not responded to cancer therapies. - For Phase II, people ages 3 31 with a Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibroma (PN) that cannot be removed with surgery. Design: - Participants will be screened with: - Medical history - Physical exam - Blood and urine tests - Heart tests - Scans or other tests of the tumor - Participants will take PLX3397 as a capsule once daily for a 28-day cycle. They can do this for up to 2 years. - During the study, participants will have many tests and procedures. They include repeats of the screening tests. Participants will keep a diary of symptoms. - Participants with solid tumors will have scans or x-rays. - Participants with NF1 PN will have MRI scans. - Participants with leukemia will have blood tests. They may have a bone marrow sample taken. - Some participants may have a biopsy. - When finished taking PLX3397, participants will have follow-up visits. They will repeat the screening tests and note side effects. - Phase II will follow the same procedures as Phase I above, but participants will also fill out questionnaires about their pain and quality of life.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland